NCCN Recommends ctDNA-MRD Testing Using Signatera™ Technology in Landmark Bladder Cancer Guideline Update
Go back to NCCN Recommends ctDNA-MRD Testing Using Signatera™ Technology in Landmark Bladder Cancer Guideline Update| (NASDAQ: NTRA) | Delayed: 264.22 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $264.22 | 52 Week High | $13.80 | |||
| Open | $264.22 | 52 Week Low | $6.52 | |||
| Day High | $264.22 | P/E | N/A | |||
| Day Low | $264.22 | EPS | $0.00 | |||
| Volume | 1,107 | |||||
